Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

References

• Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110(8):3064–3070.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–4699.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947–1954.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004;32(4):397–407.
   PubMed Web of Science ®Google Scholar
• Oran B, Wagner JE, DeFor TE, et al. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17(9):1327–1334.
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347.
   PubMed Web of Science ®Google Scholar
• Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839.
   PubMed Web of Science ®Google Scholar
• Pineault N, Abu-Khader A. Advances in umbilical cord blood stem cell expansion and clinical translation. Exp Hematol. 2015;43(7):498–513.
   PubMed Web of Science ®Google Scholar
• Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31(6):535–544.
   PubMed Web of Science ®Google Scholar
• Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009;43(6):447–454.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Dave H, Bollard CM, et al. Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investig. 2017;4:41.
   PubMedGoogle Scholar
• Stasi R, Bosworth J, Rhodes E, et al. Thrombopoietic agents. Blood Rev. 2010;24(4–5):179–190.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227–2236.
   PubMed Web of Science ®Google Scholar
• Sun H, Tsai Y, Nowak I, et al. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. http://www.ctep.cancer.gov. Published: November 27, 2017.
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15(6):825–828.
   Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
   PubMed Web of Science ®Google Scholar
• Blume KF, Appelbaum FR. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. hematopoietic cell transplantation. Oxford, UK: Blackwell; 2004. p. 234–243.
   Google Scholar
• Kristt D, Israeli M, Narinski R, et al. Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples. J Biomol Tech. 2005;16(4):380–391.
   PubMedGoogle Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846.
   PubMed Web of Science ®Google Scholar
• Liesveld JL, Phillips GL, Becker M, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013;19(12):1745–1752.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Inamoto Y, Yamashita T, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(5):919–924.
   PubMed Web of Science ®Google Scholar
• Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65–e73.
   PubMedGoogle Scholar
• Calmettes C, Vigouroux S, Tabrizi R, et al. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant. 2011;46(12):1587–1589.
   PubMed Web of Science ®Google Scholar
• Maximova N, Zanon D, Rovere F, et al. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Int J Hematol. 2015;102(5):626–632.
   PubMed Web of Science ®Google Scholar
• Hartranft ME, Clemmons AB, DeRemer DL, et al. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2017;23(1):10–17.
   PubMed Web of Science ®Google Scholar
• Battipaglia G, Ruggeri A, Brissot E, et al. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(12):1574–1577.
   PubMed Web of Science ®Google Scholar
• Solh M, Brunstein C, Morgan S, et al. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17(5):710–716.
   PubMed Web of Science ®Google Scholar
• Solves P, Sanz J, Gomez I, et al. Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. Eur J Haematol. 2019;103(3):172–177.
   PubMed Web of Science ®Google Scholar
• Tang B, Huang L, Liu H, et al. Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation. Blood Adv. 2020;4(16):3829–3839.
   PubMed Web of Science ®Google Scholar